ClinicalTrials.gg
TerminatedNCT05609942AZUREUpdated Apr 10, 2025

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

A Phase 1 interventional study of BLU-263 and Azacitidine in Advanced Systemic Mastocytosis, sponsored by Blueprint Medicines Corporation. Terminated at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

Why this study was terminated
Terminated - alignment of strategic priorities

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Mastocytosis, Systemic by Sanofi — 4 open to participants now, 5 under way, 1 of them phase 3. Mastocytosis, Systemic · Sanofi.

Started
2023
the only one that year
Phase 1
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Mastocytosis, Systemic by Sanofi, this one is the only one that started in 2023, is one of 2 in phase 1, and was the 7th registered.

Mastocytosis, Systemic

56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.

Browse Mastocytosis, Systemic studies →

Open to participants now

4 of the 10 studies in Mastocytosis, Systemic by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Mastocytosis, Systemic by Sanofi, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are:

  • Determine Recommended Dose of elenestinib (BLU-263) monotherapy for participants with AdvSM
  • Safety and tolerability of elenestinib (BLU-263) monotherapy
  • Efficacy of elenestinib (BLU-263) monotherapy in participants with AdvSM
  • Determine Recommended Dose of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM
  • Safety and tolerability of elenestinib (BLU-263) in combination with azacitidine
  • Efficacy of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM

The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.

Read the detailed description

Systemic mastocytosis includes five major subtypes: Indolent SM (ISM), SM with an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and MC leukemia (MCL). In 2016, the smoldering subtype of SM, a former provisional ISM subvariant, was designated as a distinct variant of SM by the World Health Organization (WHO). Aggressive SM, SM-AHN, and MCL together are referred to as Advanced SM (AdvSM).

03

Conditions studied

  • Advanced Systemic Mastocytosis

Keywords

  • BLU-263
  • elenestinib
  • azacitidine
  • AdvSM
  • KIT D816V
  • Advanced systemic mastocytosis
  • Mast cell leukemia
  • MCL
  • Systemic mastocytosis
  • SM
  • SM-AHN
  • CMML-2
  • Myelodysplastic/myeloproliferative neoplasms
  • MDS/MPN
  • Myeloid neoplasms
  • ASM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria :

  • Participant has (ECOG) performance status (PS) of 0-2
  • Participant must have a new Bone Marrow (BM) or may use archival tissue if taken within 56 days prior to C1D1 and participant must be willing to have follow-up BM Biopsies.
  • Participants receiving antineoplastic therapy within the preceding 12 weeks must have discontinued therapy due to disease progression, disease, lack of efficacy, or intolerance.
  • Participants treated with 1 prior selective KIT inhibitor (such as avapritinib or CGT9486) will be permitted on study after confirmation of KIT D816V mutation and with written approval of the study Sponsor. Participants who discontinued treatment with a prior selective KIT inhibitor due to a severe AE that was thought to be related to prior treatment will not be eligible to participate in the study.

Arm 1 (Monotherapy): Participants must have one of the following AdvSM diagnoses, based on World Health Organization (WHO) diagnostic criteria.

Before enrollment, diagnosis of AdvSM must be confirmed based on Central Pathology Laboratory assessment of BM:

  1. Aggressive SM (ASM).
  2. SM-AHN that in the opinion of the Investigator is not considered to be a candidate for Hypomethylating agent (HMA) monotherapy. Incidental indolent, low-grade lymphoid AHNs (eg, chronic lymphocytic leukemia) not requiring treatment are eligible.
  3. Mast cell leukemia (MCL), including diagnoses with an AHN component, that does not require a C-finding.
  4. Upon discussion with the Sponsor, other relapsed or refractory hematologic neoplasms with evidence of aberrant KIT or PDGFR may be considered for enrollment. (eg, participants with chronic myeloid neoplasms, such as subvariants of MDS/MPN that harbor activating KIT exon 17 mutations but do not fulfill the diagnostic criteria of SM-AHN, and participants with myeloid/lymphoid neoplasms with PDGFRa/b fusion genes and mutations conferring resistance to imatinib, such as T674I or D842V).

Key Exclusion Criteria:

  • Diagnosis of a Philadelphia chromosome positive
  • Acute myeloid leukemia.
  • If the participant is receiving , and the dose has not been stable for ≥7 days.
  • Within the 14 days prior to enrollment, participant has received any antineoplastic therapy (including midostaurin, avapritinib and other tyrosine kinase inhibitors [TKIs]) or an agent.
  • Participant has received hydroxyurea within 7 days prior to the first dose of elenestinib (BLU-263).
  • Participant received prior HMA therapy (e.g., azacitidine, decitabine) for the current diagnosis.
  • Participant must not be eligible for allogenic hematopoietic stem cell transplantation.
  • Participant received prior radiotherapy within 14 days of screening BM biopsy.
  • Participant received any hematopoietic growth factor (except erythropoietin) within 14 days of screening BM biopsy, or requiring growth factors to maintain adequate neutrophil or levels.

Those participants maintained on a chronic dose of erythropoietin, whose is stable, and dose of erythropoietin has not been changed in the prior 28 days are allowed on study.

  • Participant received >1 prior selective KIT inhibitor (eg: avapritinib or bezuclastinib).
  • Participant have any of the following laboratory abnormalities on last laboratory assessment within 14 days prior to the first dose of initiation of study drug: a. and aspartate aminotransferase > 3 × ; > 5 × ULN if associated with clinically suspected liver infiltration by mastocytosis or another disease for which the patient enrolled into the study b. Total > 1.5 × ULN; > 3 × ULN if associated with liver infiltration by the disease being treated or in the presence of Gilbert's Disease. (In the case of Gilbert's disease, a direct bilirubin > 2.0 ULN would be an exclusion) c. Estimated ( formula) or measured creatinine clearance \< 40 mL/min d. \< 0.5 × 10\^9/L
  • Participant has had a major surgical procedure within 14 days of the first dose of study drug.
  • History of another primary malignancy that has been diagnosed or required therapy within 1 year prior to the first dose of study drug. The following are exempt from the 1-year limit: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, GI stromal tumor, and completely resected carcinoma in situ of any site.
  • Mean resting > 480 msec, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome.
  • , uncontrolled, cardiovascular disease.

Arm 1 (Monotherapy):

  • Myelodysplastic Syndrome (MDS) that is very high- or high-risk as defined by the International Prognostic Scoring System for Myelodysplastic Syndromes-Revised (IPSS-R).
  • A myeloid AHN with ≥10% BM or peripheral blood blasts.
  • Platelet count \<50 x 10\^9/L (within 4 weeks prior to the first dose of study drug) or receiving platelet transfusions or thrombopoietin receptor agonists (TPO-RA) within the prior 14 days.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Monotherapy

    Participants with AdvSM (ASM, SM-AHN, or MCL) will receive BLU-263 monotherapy.

    Drug: BLU-263

  • Experimental
    Combination therapy

    Participants with high risk and very high risk systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) of non-MC lineage will receive BLU-263 in combination with azacitidine.

    Drug: BLU-263 · Drug: Azacitidine

Interventions

  • BLU-263 Oral Tablets

    Also known as: elenestinib

  • Azacitidine powder for suspension for intravenous infusion / subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Dose-limiting Toxicities (DLTs) (monotherapy only)

    Monotherapy: The Recommended Dose (RD) will be primarily determined by the number of DLTs in the first 28 days of treatment with elenestinib (BLU-263) monotherapy.

    Time frame: 28 Days

  2. Dose Escalation: Number of DLTs (combination therapy only)

    Combination therapy: The RD will be primarily determined by the number of DLTs (during 28 days starting from Day 15 of C1 or Day 15 of C2) with elenestinib (BLU-263) in combination with azacitidine.

    Time frame: 28 Days

  3. Dose Escalation and Expansion: Pure Pathological Response (PPR) Rate for SM in Selective KIT Inhibitor-naïve Participants (monotherapy only)

    PPR Rate is defined as complete remission (resolution of palpable splenomegaly/hepatomegaly) (CR) + complete remission with partial recovery of peripheral blood counts (CRh) + partial remission (≥35% reduction in spleen volume) (PR)

    Time frame: Up to approximately 4 years

  4. Dose Escalation and Expansion: Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 4 years

  5. Dose Escalation and Expansion: Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Dose Escalation and Expansion: Overall Response Rate (ORR) for AdvSM using modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (IWG-MRT-ECNM) (monotherapy only)

    ORR is defined as CR + CRh + PR + Clinical Improvement (CI)

    Time frame: Up to approximately 4 years

  2. Dose Escalation and Expansion: ORR for SM Using Modified IWG-MRT-ECNM (combination therapy only)

    Time frame: Up to approximately 4 years

  3. Dose Escalation and Dose Expansion: Maximum Plasma Concentration (Cmax) of BLU-263

    Time frame: Up to approximately 4 years

  4. Dose Escalation and Dose Expansion: Cmax of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  5. Dose Escalation and Dose Expansion: Time to Maximum Concentration (Tmax) of BLU-263

    Time frame: Up to approximately 4 years

  6. Dose Escalation and Dose Expansion: Tmax of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  7. Dose Escalation and Dose Expansion: Area Under the Curve From Time Zero to 24 Hours (AUC(0-24)) of BLU-263

    Time frame: Up to approximately 4 years

  8. Dose Escalation and Dose Expansion: AUC(0-24) of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  9. Dose Escalation and Dose Expansion: Apparent Volume of Distribution (Vz/F) of BLU-263

    Time frame: Up to approximately 4 years

  10. Dose Escalation and Dose Expansion: Vz/F of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  11. Dose Escalation and Dose Expansion: Terminal Elimination Half-life (t1/2) of BLU-263

    Time frame: Up to approximately 4 years

  12. Dose Escalation and Dose Expansion: t1/2 of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  13. Dose Escalation and Dose Expansion: Apparent Oral Clearance (CL/F) of BLU-263

    Time frame: Up to approximately 4 years

  14. Dose Escalation and Dose Expansion: CL/F of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  15. Dose Escalation and Dose Expansion: Accumulation Ratio of BLU-263

    Time frame: Up to approximately 4 years

  16. Dose Escalation and Dose Expansion: Accumulation Ratio of Azacitidine (combination therapy only)

    Time frame: Up to approximately 4 years

  17. Dose Escalation and Expansion: Overall Survival (OS) (monotherapy only)

    Time frame: Up to approximately 4 years

  18. Dose Escalation and Expansion: Time to Response (TtR) (monotherapy only)

    Time frame: Up to approximately 4 years

  19. Dose Escalation and Expansion: Duration of Response (DOR) (monotherapy only)

    Time frame: Up to approximately 4 years

  20. Dose Escalation and Expansion: Progression-Free Survival (PFS) (monotherapy only)

    Time frame: Up to approximately 4 years

  21. Dose Escalation and Expansion: Proportion of Participants Pursuing Stem Cell Transplant (monotherapy only)

    Time frame: Up to approximately 4 years

  22. Dose Escalation and Expansion: PPR Rate for SM (combination therapy only)

    Time frame: Up to approximately 4 years

07

Study locations

11 sites
  • Stanford Cancer Institute
    Palo Alto, California 94305, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • CHU Caen - Institut d'Hematologie de Basse Normandie
    Caen, 14033, France
  • University Medical Centre Mannheim
    Mannheim, 68167, Germany
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Oslo University Hospital
    Oslo, 0450, Norway
  • Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast)
    Toledo, 45071, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Jan 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 8, 2022
StartActual
Sep 25, 2023
Primary completionActual
Jan 14, 2025
CompletionActual
Mar 10, 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05609942
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Sep 25, 2023
Primary completion
Jan 14, 2025
Completion
Mar 10, 2025
Last update
Apr 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elenestinib

Start the discussion